Intelligence · Patent portfolio
United Therapeutics Europe Patents
Full USPTO pharma patent portfolio for United Therapeutics Europe — grant dates, expiration, and drug cross-links.
- Patents
- 3,720
- Expiring ≤24m
- 234
Quick answer
United Therapeutics Europe has 3,720 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 234 expire within 24 months — use filters for patent-cliff planning.
-
US 10039741
Use of delta tocopherol for the treatment of lysosomal storage disorders
granted -
US 10040826
Human immunodeficiency virus type 1 (HIV-1) N-terminal deleted GP120 immunogens
granted -
US 10039738
Ulcer treatment
granted -
US 10039818
Attenuated pasteurella multocida strains
granted -
US 10035848
Antibody targeting cell surface deposited complement protein C3d and use thereof
granted -
US 10035844
Broadly neutralizing HIV-1 VRC07 antibodies that bind to the CD4-binding site of the envelope protein
granted -
US 10035845
Neutralizing antibodies to HIV-1 and their use
granted -
US 10035833
Vascular endothelial growth factor antagonists and methods of making
granted -
US 10036020
Compositions and methods for inhibiting JC virus (JCV)
granted -
US 10034936
Method of inducing a cross-reactive HIV-1 immune response by administering a composition comprising the GBV-C E2 protein
granted -
US 10035832
HLA-A24 agonist epitopes of MUC1-C oncoprotein and compositions and methods of use
granted -
US 10022347
Compositions and methods for diagnosis and treatment of metabolic syndrome
granted -
US 10016463
Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells
granted -
US 10016432
Methanocarba derivatives of pseudoribose that inhibit adenosine kinase
granted -
US 10016480
Peptide-based methods for treating pancreatic cancer
granted -
US 10017543
Prefusion RSV F proteins and their use
granted -
US 10017516
BMP inhibitors and methods of use thereof
granted -
US 10017762
Compositions and methods for treating or preventing lupus
granted -
US 10010508
MTAB-TA-Coated gold nanorods and method of fabrication
granted -
US 10004800
Antibody evolution immunogens
granted -
US 9999591
Immunogenic composition against Campylobacter jejuni
granted -
US 10000813
Method of diagnosing and treating cancer using B-catenin splice variants
granted -
US 10001483
Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers
granted -
US 10000556
Single-domain VHH antibodies directed to norovirus GI.1 and GII.4 and their use
granted -
US 9993660
Method of using laser-induced optoacoustics for the treatment of drug-resistant microbial infections
granted -
US 9987330
Methods of treating or preventing pruritis by blocking natriuretic polypeptide B
granted -
US 9988334
Salts of treprostinil
granted -
US 9982025
Monomeric griffithsin tandemers
granted -
US 9974851
Human rotavirus vaccine strains and diagnostics
granted -
US 9974801
Methods of treating and preventing diseases and disorders of the central nervous system
granted -
US 9975925
Influenza antigens and antibodies
granted -
US 9975926
Methods of making and using vaccines utilizing minicircle DNA expression vectors for production of foot-and-mouth-disease virus proteins and virus-like particles
granted -
US 9974796
Inhibitors of the plasmodial surface anion channel as antimalarials
granted -
US 9976130
OPAA FL—a mutant enzyme with increased catalytic efficiency on organophosphorus compound GD
granted -
US 9975937
Heterodimers of IL-15 and IL-15R alpha to increase thymic output and to treat lymphopenia
granted -
US 9974868
Octapod iron oxide nanoparticles as high performance T2 contrast agents for magnetic resonance imaging
granted -
US 9974789
Substituted pyrazolopyrimidines as glucocerebrosidase activators
granted -
US 9968693
Small molecule imaging of fungi by positron emission tomography scanning
granted -
US 9968669
Gene optimized hantaan virus M segment DNA vaccine for hemorrhagic fever with renal syndrome
granted -
US 9970059
Survival predictor for diffuse large B cell lymphoma
granted -
US 9968641
Method to suppress the systemic toxicity of chemotherapeutic drugs
granted -
US 9962379
Inhibitors of the FKBP51 protein from a high-throughput drug screen and methods of use
granted -
US 9962390
Mosapride sustained-release formulation providing pharmacological and clinical effects with once-daily administration
granted -
US 9963450
A3 adenosine receptor agonists
granted -
US 9956267
Method of treating skeletal dysplasias using vessel dilator
granted -
US 9956278
Multivalent meningococcal conjugates and methods for preparing conjugates
granted -
US 9957486
Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization
granted -
US 9950059
Immunogenic composition
granted
Frequently asked questions
How many patents does United Therapeutics Europe have?
3,720 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do United Therapeutics Europe patents expire?
234 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory